Locally released endothelin-1 has been recently identified as an important mediator of cardiac hypertrophy. It is still unclear, however, which primary stimulus specifically activates endothelin-dependent signaling pathways. We therefore examined in adult rats (n=51) the effects of a selective ET A receptor antagonist in experimental models of cardiac hypertrophy, in which myocardial growth is predominantly initiated by a single primary stimulus. Rats were exposed to mechanical overload (ascending aortic stenosis), increased levels of circulating angiotensin II (angiotensin II infusion combined with hydralazine) or adrenergic stimulation (infusion of norepinephrine in a subpressor dose) for 7 days. All experimental treatments significantly increased left ventricular weight/body weight ratios compared with untreated rats, while systolic left ventricular peak pressure was increased only after ascending aortic stenosis. ET A receptor blockade exclusively reduced norepinephrine-induced cardiac hypertrophy and ANP gene expression. Blood pressure levels and heart rates remained unaffected during ET A receptor blockade in all experimental groups. These data indicate that in rat left ventricle the endothelin-dependent signaling pathway leading to early development of cardiac hypertrophy and fetal gene expression is primarily activated by norepinephrine.
Introduction
Endothelin (ET) is a potent vasoconstrictor which was first described by Yanasigawa and coworkers in 1988 (35) . During the past years it has become clear that in addition to its hemodynamic effects ET-1 can also act as a growth promoting hormone in the myocardium. Initial observations made on isolated cardiomyocytes revealed an increase of protein biosynthesis and cellular volume after the addition of ET-1 to the culture medium (11) . Consecutive studies in intact animals demonstrated a stimulation of the cardiac ET system in several forms of extrinsic cardiac hypertrophy, (1, 10, 12, 15, 20, 21) particularly during its early development (12, 15, 21) . Correspondingly, either selective ET A subtype receptor blockade or unselective ET A/B subtype receptor blockade significantly attenuated early myocardial hypertrophy and fetal gene expression associated with renal artery stenosis (7, 9) , suprarenal abdominal aortic banding (12) , angiotensin II (ANG II) infusion (8) , and high dose infusion of norepinephrine (NE) (15) . In all these pathophysiologically relevant models, however, several primary stimuli, which can individually induce myocardial hypertrophy, are activated concurrently, i.e. mechanical load, the renin-angiotensin system, and/or the sympathetic nervous system. Accordingly it remains unclear, whether the cardiac ET system is specifically activated, either by one or by a combined action of several primary stimuli, or whether it constitutes a more general downstream signaling pathway of myocardial growth.
In the present study we therefore sought to design experimental paradigms of extrinsically induced cardiac hypertrophy, in which myocardial growth is predominantly initiated by a single primary stimulus. To increase mechanical load to the ventricle, in one group of animals the ascending aorta was banded directly at the root of the aortic arch. In a previous study we found that this procedure does not stimulate the circulating renin-angiotensin system (33) . The observation by others that myocardial growth after ascending aortic stenosis is neither diminished by angiotensin AT-1 receptor blockade (32) nor by angiotensin converting-enzyme inhibition (37) strongly suggests that also the local cardiac renin-angiotensin system does not participate in the growth response to mechanical overload. To investigate the isolated role of circulating ANG II in ETdependent cardiac hypertrophy, in a second group of rats ANG II was chronically infused subcutaneously via osmotic minipumps. These animals also received the vasodilator hydralazine to prevent increases in blood pressure induced by the elevation of circulating ANG II levels. This experimental protocol has previously been shown to induce blood pressure-independent myocardial growth (17) . There is at present no evidence indicating any significant contribution of an increased sympathetic activity in these two experimental forms of cardiac hypertrophy. Finally, to initiate cardiac hypertrophy primarily via a stimulation of myocardial α 1 /ß 1 -adrenoceptors (36), a third group of animals received chronic infusions of NE at a low dose (100 µg/kg body weight per min). To assess the participation of the ET system in each of these experimental forms of extrinsic cardiac hypertrophy, animals were treated with either saline or the ET A receptor antagonist LU 135252 (27) .
Methods

Experimental groups
Experiments were made in a total of 51 female Sprague-Dawley rats weighing 180-200 g (9 weeks old). All surgical procedures were performed under anesthesia with ketamine/xylazine (100 mg/kg body weight and 4 mg/kg body weight, respectively).
Constriction of the ascending aorta was performed as described previously ANG II was 
RNA analysis
RNA was extracted from ventricles pulverized under liquid nitrogen (5). It was confirmed that the probes used for mRNA analysis hybridized to a single band of the appropriate molecular weight by Northern blot analysis (33) . For quantification, RNA was blotted to nitrocellulose in serial dilutions (4, 2, 1 µg RNA/slot) using a vacuum filtration slot blot apparatus. Blots were probed consecutively with cDNA probes specific for ANP mRNA (plasmid containing a 145 bp, PCR derived sequence of rat preproANP mRNA was kindly donated by Prof. Forssmann, Hannover), and 28 S rRNA under conditions described in detail previously (7) . Autoradiographs of the slot blots were scanned densitometrically and tissue levels of ANP mRNA were expressed as arbitrary densitometric units/28 S densitometric units taking care that the signal was in the linear range for all measurements.
Statistical analysis
Statistical analysis was performed using GRAPH-PAD PRISM software. 
Results
The effects of the different experimental interventions to induce cardiac hypertrophy are summarized in Table 1 (Fig. 2) . In contrast, both increase in left ventricular mass as well as stimulation of left ventricular ANP gene expression were significantly reduced by >50% in rats with NE-induced cardiac hypertrophy (Fig. 3) . In all three treatment groups, chronic ET A receptor blockade by LU 135252 remained without effects on blood pressure and heart rate (Figures 1-3) .
Discussion
The present results demonstrate that neither an increase in mechanical load nor elevated levels of ANG II without concurrent changes in blood pressure induce cardiac hypertrophy or ANP gene expression via the ET A receptor signaling pathway within 7 days after induction. In contrast, blockade of ET A receptors significantly attenuated NEinduced cardiac growth and ANP gene expression. These data suggest that the myocardial ET signaling pathway mediating early cardiac hypertrophy and ANP gene expression is primarily activated by NE.
The finding that cardiac hypertrophy caused by an increase in mechanical load was unaffected by ET A receptor blockade seems to be at variance with an earlier study by Ito et al. (12) who observed a significant reduction of cardiac remodeling by the selective ET A receptor blocker BQ-123. In contrast to the present study, these investigators used suprarenal abdominal aortic banding, which resembles the experimental model of 1-kidney, 1 clip hypertension, to induce an elevation of blood pressure. In dogs, suprarenal abdominal aortic banding has been shown to activate the renin-angiotensin system, whereas PRA did not change after ascending aortic banding because of an elevated cardiac filling pressure causing an increased release of ANP and a stimulation of cardiac mechanoreceptors (18) . In a previous study we could show that also in rats subjected to ascending aortic stenosis PRA remains unchanged (33) . Since PRA was not determined In these studies, however, blood pressure increased considerably in response to ANG II, and ET antagonism significantly reduced this hypertension (6, 8, 22, 26) . Similarly, cardiac hypertrophy associated with renovascular hypertension was largely blunted by administration of a selective ET A receptor antagonist, particulary during the early pressure-independent phase (7). Long-term ET A receptor blockade in rats with renovascular hypertension did not affect blood pressure or cardiac hypertrophy, but completely prevented vascular remodeling of intramyocardial arteries (9) . Again, it is important to note that renovascular hypertension does not represent a condition with a pure stimulation of the renin-angiotensin system, but is associated with a marked increase of sympathetic activity and the release of NE in both experimental animal models (16) as well as humans (13) . The present observations of a lack of effect of ET A receptor blockade on left ventricular hypertrophy and ANP gene expression induced by a "pure" elevation of circulating ANG II levels may therefore suggest that the inhibitory influences of ET antagonism found in these former studies may have been secondary to alterations in blood pressure and / or sympathetic activity.
A reduction of cardiac hypertrophy induced by chronic NE infusions was recently also found after unselective ET A/B receptor blockade by bosentan (15) . In contrast to the present study, however, left ventricular ANP gene expression remained unaffected. One possible explanation for this discrepancy may be related to differences in ET antagonism (selective vs. nonselective blockade). Alternatively, the much higher dose of 600 ng/ body weight per min of NE used by Kaddoura and coworkers (15) may have elicited different responses in myocardial gene expression. In preliminary experiments, we found that chronic infusion of NE at this rate was lethal within 48 hours after surgery in 80 % of infused rats. In the surviving animals, we observed a very pronounced increase in LV weight to body weight ratios and marked increases in blood pressure by 40-50 mmHg. Unfortunately, blood pressures were not reported by Kaddoura and coworkers.
Also, in the present investigation blood pressures were only determined at a single time point during anesthesia. Since cardiac unloading can cause a rapid reduction of left ventricular mass even in the presence of intense neurohumoral stimulation by ET-1 (19) , further experiments in awake rats need to be performed to clarify this issue.
A limitation of the present study is that it does not differentiate between effects on cardiomyocytes, fibroblasts, and extracellular matrix. Accumulating evidence suggests that ET-dependent signaling may significantly affect cardiac fibrosis in various forms of cardiac hypertrophy (1, 9, 23) . It seems very likely that the primary stimuli investigated here (mechanical load, ANG II, and NE) contribute to different extents to those different aspects of cardiac remodeling. Their individual, precise effects on collagen deposition, increase in extracellular matrix, and activation of cardiac fibroblasts cannot be estimated from the present study. It should be noted, however, that the increase in interstitial volume observed in early stages of cardiac hypertrophy does not exceed ~1-2% of total volume (1, 9, 32) . In the present study, left ventricular weight to body weight ratios increased by 18-39% (Table 1 ). This indicates that most of the increase in left ventricular mass in response to all three primary stimuli can be attributed to cardiomyocyte hypertrophy.
Perspectives
The present findings imply a major role for an interaction between the sympathetic nervous system (or circulating catecholamines) and the myocardial ET system during the early development of cardiac hypertrophy. This is particularly interesting from a pathogenic point of view, as several studies suggest that ET-1 may act as a "triggering factor" for myocardial growth (12, 15, 21) . Isolated cardiac myocytes display a hypertrophic response upon α-adrenergic stimulation (30, 31) , and it has recently been shown that the α 1 -adrenoreceptor agonist phenylephrine induces ET-1 gene expression and accelerates the conversion of big ET to bioactive ET-1 in cultured neonatal cardiomyocytes (14) . Stimulation of the cardiac ET system upon adrenergic activation therefore appears to constitute an important signaling pathway of early myocardial growth, which may initiate cardiomyocyte hypertrophy even in pathophysiological states without obvious catecholamine excess like renal artery stenosis (7) . The therapeutic value of ET antagonism for the treatment of cardiac hypertrophy, however, remains to be clarified. While blocking the ET system has been shown to prevent excessive myocardial hypertrophy in cardiac failure (29) , it may also be harmful under pathophysiological conditions like myocardial infarction, when early compensatory cardiac growth induced by adrenergic stimulation is required. Blood pressures refer to systolic peak pressures determined either in the left ventricle Moser et al. Figure 3 
